电磁追踪经会阴MRI/超声融合靶向活检的前列腺癌检出及阅片者间差异影响
本研究纳入176例mpMRI可疑病灶患者,同期行经会阴系统活检与电磁追踪经会阴靶向活检。总体癌检出率76.7%,靶向活检敏感性90.4%,系统活检85.9%;PI-RADS评分判别临床显著癌的AUC为0.74,优于PSA和PSAD;不同阅片者AUC似有较大差异,未发生不良事件。
要点
- 电磁追踪经会阴靶向活检对临床显著前列腺癌敏感性高于系统活检。
- PI-RADS评分判别临床显著癌的AUC为0.74,优于PSA和PSAD。
- 不同mpMRI阅片者AUC似有较大差异,提示质控必要。
核心结论
- 电磁追踪经会阴靶向活检联合系统活检可提高前列腺癌检出,对临床显著癌敏感性更高,且安全无不良事件。
研究设计与样本
- 176例mpMRI可疑病灶患者同期接受经会阴12针系统活检和电磁追踪经会阴靶向活检。
- 按PI-RADS v2评分分层比较癌检出率,计算PSA、PSAD、PI-RADS及不同阅片者AUC。
主要发现
- 总体癌检出率76.7%(135/176),其中临床显著癌占76.3%(103/135)。
- 靶向活检检出90.4%(122/135)前列腺癌,系统活检遗漏14%(19/135),其中14例为临床显著癌。
- 靶向活检和系统活检敏感性分别为90.4%和85.9%。
- 每病灶分析PI-RADS评分AUC 0.74,PSA AUC 0.59,PSAD AUC 0.63。
关键数值与推荐
- PI-RADS评分判别临床显著癌AUC 0.74,优于PSA(0.59)和PSAD(0.63)。
- 不同mpMRI阅片者AUC似有较大差异,但未进行正式统计学检验。
临床怎么用
- 对mpMRI可疑病灶患者,经会阴靶向活检可作为系统活检的补充以提高检出。
- 实施MRI筛查项目时需评估阅片者间差异并纳入质控。
局限性
- 不同阅片者AUC差异未进行正式统计学检验。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To evaluate the ability to detect clinically significant prostate cancer (PCa) using a novel electromagnetically (EM) tracked transperineal magnetic resonance imaging (MRI)/ultrasonography (US) fusion-guided targeted biopsy (transperineal TBx) platform and the impact of inter-reader variability on cancer detection. MATERIALS AND METHODS: A total of 176 patients with suspicious lesions detected on multiparametric MRI (mpMRI) underwent a systematic modified Barzel template biopsy (12-core) transperineal biopsy (transperineal SBx) and transperineal TBx with EM tracking (UroNav; Philips Healthcare, Best, the Netherlands) in the same setting. Cancer detection rates (CDRs) were stratified by Prostate Imaging Reporting and Data System (PI-RADS) v2 scores and compared with Fisher's exact test. Area under the curve (AUC) was calculated for prostate-specific antigen (PSA), PSA density (PSAD), PI-RADS score, and subgroup analysis of individual readers' PI-RADS scores with respect to overall CDR and clinically significant CDR. RESULTS: The overall CDR was 76.7% (135/176), of which 76.3% (103/135) was clinically significant PCa. Among the 135 patients with PCa, transperineal TBx detected 90.4% of cases (122/135), either alone or in combination with transperineal SBx. The remaining 9.6% of cases (13/135) missed by transperineal TBx were diagnosed by transperineal SBx alone, of which three were clinically significant. Conversely, transperineal SBx missed 14% of cases (19/135), 14 of which were clinically significant PCa. Sensitivities for transperineal TBx and transperineal SBx were 90.4% and 85.9%, respectively. On a per-lesion basis, PI-RADS score (AUC 0.74) outperformed both PSA (AUC 0.59) and PSAD (AUC 0.63) in discriminating clinically significant from non-clinically significant PCa on transperineal TBx. Although not formally statistically tested, AUCs amongst different mpMRI readers appeared to display considerable variability. There were no adverse events, including sepsis. CONCLUSIONS: Electromagnetically tracked transperineal TBx of MRI-visible lesions enhanced the ability of transperineal SBx to detect PCa, with greater sensitivity for clinically significant disease. These findings suggest transperineal TBx is a safe, alternative fusion platform for patients with a suspicious lesion on prostate MRI. The assessment of inter-reader variability, in conjunction with prediction of clinically significant PCa and CDR, is an important first step for quality control in implementing an MRI-based screening programme.
引用
- Wajswol E, Winoker JS, Anastos H, et al. A cohort of transperineal electromagnetically tracked magnetic resonance imaging/ultrasonography fusion-guided biopsy: assessing the impact of inter-reader variability on cancer detection. BJU Int. 2019. PMID: 31762182. doi:10.1111/bju.14957
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。